霍奇金淋巴瘤治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按治疗类型(化疗、放疗和其他)和地理划分

市场快照

Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 12.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

霍奇金淋巴瘤是一种由淋巴系统中称为淋巴细胞的细胞发展而来的恶性肿瘤。癌症的组织学特征是存在称为 Reed-Sternberg 细胞的多核巨细胞和相关的异常、较小的单核细胞,这些细胞来源于淋巴组织生发中心的 B 淋巴细胞。全球统计数据显示,每年每 100,000 名男性和女性中有 2.6 例新发霍奇金淋巴瘤病例。与大多数癌症不同,霍奇金淋巴瘤的发病率不会随着年龄的增长而增加;他们发现在两个年龄组,年轻人和老年人中都很高。每年确诊的新病例数量的增加预计将推动霍奇金淋巴瘤治疗市场。

报告范围

根据报告的范围,霍奇金淋巴瘤 (HL) 是一种淋巴瘤,其中癌症起源于淋巴细胞。 

By Treatment Type
Chemotherapy
Radiotherapy
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

放射治疗部门预计将在预测期内实现显着增长

根据治疗类型,它分为化疗、放疗和其他。放射疗法是一种通过使用高能束或粒子杀死癌细胞来破坏霍奇金病细胞的成熟技术,并且可以从体外的来源递送,即外部束辐射或内部,例如近距离放射疗法。对于经典的霍奇金病,放疗通常在化疗后进行,尤其是当肿瘤肿块很大或很大时。根据美国癌症协会的数据,2019 年,美国约有 8,110 人被诊断出患有霍奇金淋巴瘤。因此,癌症负担的增加,以及对霍奇金淋巴瘤的认识不断提高,预计市场将在预测期内增长。

Hodgkin Lymphoma Treatment Market 1

北美有望在霍奇金淋巴瘤治疗市场占据最大份额

霍奇金淋巴瘤治疗市场预计将在北美地区占据最大份额。根据美国癌症协会的估计,2019 年美国约有 1,000 人死于霍奇金淋巴瘤(410 名女性和 590 名男性)。霍奇金淋巴瘤影响儿童和成人。它是 15 至 19 岁青少年最常被诊断出的癌症。越来越多的新病例、发达的医疗保健基础设施和先进的治疗方案正在促进所研究市场的增长。

Hodgkin Lymphoma Treatment Market 2

竞争格局

进入霍奇金淋巴瘤治疗市场的全球参与者有 Alkem Laboratories、Amneal Pharmaceuticals, Inc.、Baxter International Inc.、Biogen Inc.、Bristol-Myers Squibb Company、F Hoffmann-La Roche Ltd、Incyte Corp、Merck & Co. Inc.。 、西雅图遗传学公司和梯瓦制药工业有限公司。

主要玩家

  1. Amneal Pharmaceuticals, Inc.

  2. Biogen Inc.

  3. Bristol-Myers Squibb Company

  4. Merck & Co. Inc.

  5. Seattle Genetics, Inc.

Hodgkin Lymphoma Treatment Market - 2

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Hodgkin Lymphoma

      2. 4.2.2 Increasing Awareness about Hodgkin Lymphoma

      3. 4.2.3 High Unmet Need in Older Patients and Patients with Relapsed or Refractory (R/R) HL

    3. 4.3 Market Restraints

      1. 4.3.1 Adverse Long-term Side Effects

      2. 4.3.2 High Cost of Treatment

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment Type

      1. 5.1.1 Chemotherapy

      2. 5.1.2 Radiotherapy

      3. 5.1.3 Others

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle-East and Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle-East and Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Alkem Laboratories

      2. 6.1.2 Amneal Pharmaceuticals, Inc.

      3. 6.1.3 Baxter International Inc.

      4. 6.1.4 Biogen Inc.

      5. 6.1.5 Bristol-Myers Squibb Company

      6. 6.1.6 F Hoffmann-La Roche Ltd

      7. 6.1.7 Incyte Corp

      8. 6.1.8 Merck & Co. Inc.

      9. 6.1.9 Seattle Genetics, Inc.

      10. 6.1.10 Teva Pharmaceutical Industries Ltd.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Hodgkin Lymphoma Treatment Market market is studied from 2018 - 2026.

The Hodgkin Lymphoma Treatment Market is growing at a CAGR of 12.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Amneal Pharmaceuticals, Inc., Biogen Inc., Bristol-Myers Squibb Company, Merck & Co. Inc., Seattle Genetics, Inc. are the major companies operating in Hodgkin Lymphoma Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!